TELA Bio, Inc. (NASDAQ: TELA) is proud to share the results of six groundbreaking studies published in 2022, which demonstrate the efficacy of their revolutionary OviTex Reinforced Tissue Matrix product. The data from these studies demonstrate that OviTex is a superior alternative to traditional synthetic and biologic mesh products, providing patients with significantly improved clinical outcomes. TELA Bio is committed to providing innovative soft-tissue reconstruction solutions that prioritize the preservation and restoration of the patient’s own anatomy.
This year, more than two million hernia repairs will be conducted around the world, and the use of hernia reinforcement materials is of utmost importance for surgeons and patients alike. By reinforcing the area of repair, the risk of infection and hernia recurrences is greatly reduced. It is essential that these materials are used in all hernia repairs to ensure the safety and success of the procedure.
Since its commercialization in June 2016, OviTex Reinforced Tissue Matrix has seen a wealth of clinical evidence supporting its efficacy. Studies across Europe and the United States have demonstrated promising results for OviTex when compared to both pure biologics and permanent synthetics. 280 patients have been examined in both prospective and retrospective studies, and three studies directly compared OviTex to other treatments. The results showed lower complication and recurrence rates for OviTex in comparison to pure biologics, as well as lower surgical site occurrences and similar recurrence rates for OviTex in comparison to permanent synthetics. OviTex has proven to be a reliable and effective choice for many patients.
Marissa Conrad, Vice President of Clinical Affairs, is delighted to present these six studies. With increased education amongst hernia patients on their treatment options, it’s essential they’re aware of the published research demonstrating the efficacy of natural materials available for their repair.
OviTex Reinforced Tissue Matrix is designed to strengthen and mend weakened soft tissue, such as that found in hernias and abdominal wall defects. This versatile mesh material provides a durable, reliable solution to these medical issues. However, patients allergic to materials of ovine (sheep) origin should not use OviTex. As with any surgical procedure, there are risks of adverse events including pain, infection, hernia recurrence, adhesion, bowel obstruction, bleeding, fistula, seroma, perforation, mesh migration, and mesh contraction. But with OviTex, you can rest assured that you are getting a superior product that can help you tackle your medical issues head-on.
About TELA Bio, Inc.
TELA Bio, Inc. (NASDAQ: TELA) is revolutionizing the medical technology industry with innovative solutions that prioritize the preservation and restoration of a patient’s own anatomy. By leveraging the patient’s natural healing response and minimizing the need for long-term exposure to permanent synthetic materials, TELA Bio is dedicated to providing surgeons with advanced and economically effective soft-tissue reconstruction solutions. With these solutions, the company is optimizing clinical outcomes and transforming the healthcare industry.